A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cance

A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM) is a phase 2, interventional study registered as NCT07797244 by Dai, Guanghai, with a registry enrolment figure of 46 participants, started 2026-10-29 and due to reach its primary completion in 2029-04. Interventions recorded: Retlirafusp alfa+XELOX+Bevacizumab Treatment. Conditions listed: Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM). Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: "Unresectable colorectal adenocarcinoma confirmed by histopathology or cytology;". Sites: China. No results are recorded here; the registry entry is the source.